Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X4P-001 dosing in healthy volunteers
NCT02680782Phase 1Terminated
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Jan 2016
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mavorixafor in WHIM syndrome (WHIM) (2 arms), sponsored by X4 Pharmaceuticals, Inc. Primary endpoints: Incidence of treatment emergent adverse events, Maximum Plasma Concentration and 2 more. Started Jan 2016; status: terminated.
02
Drugs
mavorixafor
03
Conditions
WHIM syndrome (WHIM)
Beyond the preview
Go deeper on NCT02680782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680782.